Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Limbo: FDA Will Not Have Access To Extra Industry Funds At FY 2013 Start

This article was originally published in The Gray Sheet

Executive Summary

The new fiscal year starts Oct. 1, but FDA will not be able to spend the full amount of fiscal year 2013 industry user fees as a result of an emergency spending bill, and Congress is not expected to fix the issue until after the election in November at the earliest.

Advertisement

Related Content

News In Brief
News In Brief
Device User Fee Fix Included In House-Passed Continuing Resolution
Washington Roundup, October 2012
Device Tax Repeal Tops AdvaMed Priority List For Fiscal-Cliff Bill
FDA Charges Ahead With MDUFA III Implementation, Despite Budget Uncertainties
News In Brief
CDRH Officials Reveal Top Challenges To Executing User Fee Updates
Congress Set To Pass Six-Month Funding Bill, As Sequestration Still Looms
FDA Subject To More Oversight Following User Fee Bill Passage

Topics

Advertisement
UsernamePublicRestriction

Register

MT031594

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel